Opioid addiction can develop gradually, and early signs are easy to mistake for fatigue, stress, pain, or changing routines. Physical warning signs such as pinpoint pupils, unusual drowsiness, and slowed breathing often appear alongside behavioral changes like secrecy, missing prescriptions, financial strain, and withdrawal from normal responsibilities.
Recognizing these patterns early can help families and individuals seek treatment before dependence, overdose risk, and long-term health consequences become more severe.
Pinpoint pupils, nodding off, slowed or shallow breathing, itching, constipation, unusual fatigue, and flu-like symptoms between doses can all signal opioid use or withdrawal.
Missing pills, doctor-shopping, secrecy, sudden financial problems, pawned belongings, missed work or school, and unexplained changes in routine may indicate escalating use.
Euphoria may alternate with irritability, anxiety, depression, defensiveness, or emotional fog as opioid effects wear off.
Needing more opioids to get the same effect or feeling sick when use stops are major warning signs that physical dependence may be developing.
| Opioid | Common Names | Possible Signs | Additional Risks |
|---|---|---|---|
| Oxycodone | OxyContin, Percocet | Euphoria followed by sedation, pinpoint pupils | Crushing or snorting can accelerate tolerance and overdose risk |
| Hydrocodone | Vicodin, Norco | Drowsiness, constipation, flu-like symptoms between doses | Combination products may contain acetaminophen, adding liver risk at high doses |
| Morphine | MS Contin, Kadian | Heavy nodding, itching, slowed digestion | Injection can increase infection and vein-damage risk |
| Fentanyl | Fetty, synthetic opioid mixtures | Very rapid sedation and severe respiratory depression | High potency increases overdose risk, especially in unpredictable illicit supplies |
| Heroin | Smack, H, Dope | Rush, flushed skin, nodding, track marks when injected | Illicit heroin may be contaminated with fentanyl or other substances |
| Tramadol | Ultram | Opioid-like sedation with possible atypical symptoms | Can increase seizure risk and interact with serotonergic medications |
Opioid addiction is recognized by major medical organizations as a chronic medical condition involving changes in brain reward, motivation, decision-making, and self-control. That helps explain why cravings, escalating use, and withdrawal can persist even when a person sincerely wants to stop.
Clinicians diagnose opioid use disorder using established substance use disorder criteria. The severity depends on how many symptoms are present and how much they interfere with daily life.
Inherited vulnerability can influence how strongly the brain responds to opioids and how quickly tolerance or compulsive use develops.
Easy access to medication, family or peer substance use, chronic pain, and community stressors can increase exposure and risk.
Anxiety, depression, PTSD, grief, and unresolved trauma can lead some people to use opioids as a form of emotional self-medication.
Legitimate opioid treatment after surgery, injury, or chronic pain can still lead to dependence in some people, especially when use continues longer than intended.
Early signs may look manageable, but opioid addiction often becomes more visible as tolerance, withdrawal, and compulsive use intensify.
| Phase | Approximate Timing | Common Symptoms |
|---|---|---|
| Early | 6–12 hours for some short-acting opioids | Restlessness, watery eyes, yawning, anxiety |
| Peak | 24–72 hours | Muscle aches, diarrhea, vomiting, sweating, strong cravings |
| Sub-acute | Several days | Fatigue, insomnia, mood swings, low energy |
| Post-acute symptoms | Weeks or longer for some people | Anxiety, depression, sleep problems, concentration difficulty |
Long-term opioid use can also contribute to hormonal disruption, chronic constipation, depression, reduced ability to experience pleasure, and other physical or emotional health problems. Detox alone does not address these longer-term risks.
Common warning signs include:
A professional assessment can determine whether these symptoms meet criteria for opioid use disorder and what level of care may be appropriate.
Opioids may temporarily reduce distress, but rebound anxiety and withdrawal can make symptoms worse over time.
Chronic opioid use can worsen depression and reduce natural reward and motivation, which may increase relapse risk.
People may use opioids to escape emotional or physical pain, creating a cycle in which trauma symptoms and opioid dependence reinforce each other.
Integrated treatment addresses substance use and mental health symptoms together instead of treating them as separate problems.
Use opioids exactly as prescribed, avoid sharing medication, and discuss tapering or non-opioid alternatives with a clinician when appropriate.
Lock medications away from others and use approved take-back or disposal options for leftovers.
Naloxone can reverse an opioid overdose and is an important safety tool for people at risk and their families.
Early conversations about tolerance, cravings, withdrawal, missing medications, or escalating use can create an opportunity for treatment before a crisis.
Effective opioid addiction treatment often combines medication, counseling, behavioral therapy, relapse prevention, and ongoing recovery support.
Buprenorphine or naltrexone may be used when clinically appropriate to reduce cravings and support recovery alongside counseling and behavioral care.
PHP provides full-day structured treatment with therapy, groups, recovery education, and clinical oversight.
IOP provides several therapy sessions per week for clients who need structure while continuing work, school, or family responsibilities.
Outpatient treatment provides flexible ongoing therapy, relapse prevention, and maintenance-focused recovery support.
Recovery continues after the first phase of treatment. Ongoing therapy, medication support when appropriate, peer recovery groups, sober living referrals, relapse-prevention planning, and healthy daily routines can help reinforce stability.
Consistent sleep, exercise, stress-management skills, supportive relationships, and continued mental health care may also reduce relapse risk and improve quality of life.
Early signs may include pinpoint pupils, unusual drowsiness, slowed breathing, missing pills, increasing secrecy, mood changes, escalating doses, and difficulty functioning at work, school, or home.
Opioid addiction can contribute to irritability, anxiety, depression, defensiveness, social withdrawal, secrecy, and changes in motivation or decision-making.
Physical signs may include pinpoint pupils, nodding off, slowed breathing, constipation, itching, track marks when opioids are injected, and flu-like symptoms between doses.
A person may spend increasing amounts of time thinking about opioids, obtaining them, using them, recovering from them, or trying unsuccessfully to cut back.
Anxiety, depression, emotional numbness, mood swings, trauma symptoms, shame, and isolation may occur alongside opioid addiction or worsen as dependence progresses.
It can lead to missed work or school, financial strain, family conflict, social isolation, neglected responsibilities, legal problems, and risky behavior.
Withdrawal can indicate physical dependence and is one of the clinical signs considered when evaluating opioid use disorder.
A professional assessment can help determine overdose risk, withdrawal needs, whether opioid use disorder is present, and what treatment options are appropriate.
Medication-assisted treatment can reduce cravings and support recovery when clinically appropriate, especially when combined with counseling and behavioral treatment.
Yes. Depending on clinical needs, PHP, IOP, outpatient treatment, and MAT can provide structured support without requiring residential treatment.
If opioid use, withdrawal, cravings, or behavioral changes are becoming concerning, Lexington Addiction Center can help you understand the next step. Admissions can discuss treatment options, verify insurance, and connect you with MAT, outpatient care, or detox support when appropriate.
MedlinePlus. (n.d.). Dual diagnosis. https://medlineplus.gov/dualdiagnosis.html
American Society of Addiction Medicine. (n.d.). About the ASAM Criteria (levels of care overview). https://www.asam.org/asam-criteria/about-the-asam-criteria Default
Substance Abuse and Mental Health Services Administration. (2020). TIP 42: Substance use treatment for persons with co-occurring disorders (PEP20-02-01-004). https://library.samhsa.gov/product/tip-42-substance-use-treatment-persons-co-occurring-disorders/pep20-02-01-004 SAMHSA Library
National Institute on Drug Abuse. (2023). Co-occurring disorders and health conditions. https://nida.nih.gov/research-topics/co-occurring-disorders-health-conditions National Institute on Drug Abuse
National Institute on Drug Abuse. (2010). Common comorbidities with substance use disorders (pp. 1–16). https://nida.nih.gov/sites/default/files/1155-common-comorbidities-with-substance-use-disorders.pdf National Institute on Drug Abuse
Magill, M., Kiluk, B. D., & Ray, L. A. (2023). Efficacy of cognitive behavioral therapy for alcohol and other drug use disorders: Is a one-size-fits-all approach appropriate? Substance Abuse and Rehabilitation, 14, 1–11. https://doi.org/10.2147/SAR.S362864 Dove Medical Press+1
SAMHSA. (2020). Using motivational interviewing in substance use disorder treatment (Advisory 35; PEP20-02-02-014). https://library.samhsa.gov/sites/default/files/PEP20-02-02-014.pdf SAMHSA Library
Linehan-informed review: Dialectical behavior therapy for individuals with substance use problems (2019). In Dialectical Behavior Therapy (pp. 139–160). https://www.sciencedirect.com/science/article/pii/B9780128163849000075 ScienceDirect
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of PTSD and ASD (EMDR “Strong for” recommendation). https://www.ptsd.va.gov/professional/treat/txessentials/cpg_ptsd_management.asp PTSD VA
National Institute on Drug Abuse. (2025). Medications for opioid use disorder (overview). https://nida.nih.gov/research-topics/medications-opioid-use-disorder National Institute on Drug Abuse
Substance Abuse and Mental Health Services Administration. (2021). TIP 63: Medications for opioid use disorder (PEP21-02-01-002). https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
Addiction and co-occurring disorders don’t have to control your life. Lexington Addiction Center is waiting with open arms to give you the tools necessary for lasting change. Reach out to us today to learn more.
